Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

IGF1R signalling and its inhibition.

Riedemann J, Macaulay VM.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S33-43. Review.

2.

Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment.

Bohula EA, Playford MP, Macaulay VM.

Anticancer Drugs. 2003 Oct;14(9):669-82. Review.

PMID:
14551500
3.

Development of molecular agents for IGF receptor targeting.

Salisbury AJ, Macaulay VM.

Horm Metab Res. 2003 Nov-Dec;35(11-12):843-9. Review.

PMID:
14710367
4.

The IGF receptor as anticancer treatment target.

Macaulay VM.

Novartis Found Symp. 2004;262:235-43; discussion 243-6, 265-8. Review.

PMID:
15562833
5.
6.

[Insulin-like growth factor (IGF)-signalling pathway components are potential therapeutic targets in the treatment of human hepatocellular carcinoma].

Nussbaum T, Samarin J, Schirmacher P, Breuhahn K.

Verh Dtsch Ges Pathol. 2007;91:278-85. German.

PMID:
18314625
7.

The therapeutic potential of agents targeting the type I insulin-like growth factor receptor.

Zhang H, Yee D.

Expert Opin Investig Drugs. 2004 Dec;13(12):1569-77. Review.

PMID:
15566314
8.
10.

Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.

Tao Y, Pinzi V, Bourhis J, Deutsch E.

Nat Clin Pract Oncol. 2007 Oct;4(10):591-602. Review.

PMID:
17898809
11.

A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.

Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D.

J Biol Chem. 2004 Feb 6;279(6):5017-24. Epub 2003 Nov 13.

12.

A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.

Martins AS, Ordoñez JL, García-Sánchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gúrpide J, de Alava E.

Cancer Res. 2008 Aug 1;68(15):6260-70. doi: 10.1158/0008-5472.CAN-07-3074.

13.

The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript.

Bohula EA, Salisbury AJ, Sohail M, Playford MP, Riedemann J, Southern EM, Macaulay VM.

J Biol Chem. 2003 May 2;278(18):15991-7. Epub 2003 Feb 24.

14.

Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.

Mitsiades CS, Mitsiades N.

Expert Rev Anticancer Ther. 2005 Jun;5(3):487-99. Review.

PMID:
16001956
15.

Epitope-specific mechanisms of IGF1R inhibition by ganitumab.

Calzone FJ, Cajulis E, Chung YA, Tsai MM, Mitchell P, Lu J, Chen C, Sun J, Radinsky R, Kendall R, Beltran PJ.

PLoS One. 2013;8(2):e55135. doi: 10.1371/journal.pone.0055135. Epub 2013 Feb 1.

16.

Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.

Hendrickson AW, Haluska P.

Curr Opin Investig Drugs. 2009 Oct;10(10):1032-40. Review.

PMID:
19777391
17.

Insulin-like growth factor signaling regulates zebrafish embryonic growth and development by promoting cell survival and cell cycle progression.

Schlueter PJ, Peng G, Westerfield M, Duan C.

Cell Death Differ. 2007 Jun;14(6):1095-105. Epub 2007 Mar 2.

19.

Insulin-like growth factor-I receptor signaling blockade combined with radiation.

Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ, Harari PM.

Cancer Res. 2007 Feb 1;67(3):1155-62.

20.

Supplemental Content

Support Center